-$0.43 EPS Expected for Scpharmaceuticals Inc (NASDAQ:SCPH) This Quarter
Equities analysts expect Scpharmaceuticals Inc (NASDAQ:SCPH) to report earnings of ($0.43) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Scpharmaceuticals’ earnings, with estimates ranging from ($0.48) to ($0.37). Scpharmaceuticals posted earnings of ($0.31) per share during the same quarter last year, which would indicate a negative year over year growth rate of 38.7%. The business is scheduled to report its next earnings report on Tuesday, November 12th.
According to Zacks, analysts expect that Scpharmaceuticals will report full year earnings of ($1.77) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.59). For the next year, analysts anticipate that the firm will post earnings of ($1.59) per share, with EPS estimates ranging from ($2.15) to ($1.02). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Scpharmaceuticals.
Scpharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.10.
Shares of NASDAQ:SCPH traded up $0.27 on Thursday, hitting $5.27. 3,400 shares of the company’s stock were exchanged, compared to its average volume of 57,131. The firm’s 50-day moving average is $5.71 and its 200 day moving average is $4.85. The company has a debt-to-equity ratio of 0.10, a quick ratio of 6.04 and a current ratio of 6.04. The company has a market capitalization of $102.19 million, a PE ratio of -3.31 and a beta of 0.79. Scpharmaceuticals has a 1-year low of $2.44 and a 1-year high of $7.85.
Several hedge funds have recently modified their holdings of the company. Eversept Partners LP purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth approximately $556,000. Alambic Investment Management L.P. purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth approximately $191,000. Jacobs Levy Equity Management Inc. raised its stake in shares of Scpharmaceuticals by 55.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after buying an additional 13,225 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Scpharmaceuticals during the 2nd quarter worth approximately $96,000. Finally, Matisse Capital purchased a new position in shares of Scpharmaceuticals during the 3rd quarter worth approximately $86,000. 39.75% of the stock is owned by institutional investors and hedge funds.
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Further Reading: Stocks at 52 Week High
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.